SOMERVILLE, Mass.--(BUSINESS WIRE)--Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, today announced the appointment of Percy Carter, MBA, Ph.D., as a member of its Board of Directors.
Dr. Carter currently serves as Chief Scientific Officer at Blueprint Medicines and formerly held several leadership roles in the biopharma industry, including Global Head of Discovery Sciences at Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), and Senior Vice President and Head of Discovery at Bristol Myers Squibb (BMS).
Dr. Carter comes to Cellarity’s Board with a strong track record of shaping and leading drug discovery and platform development. As CSO of Blueprint Medicines, Dr. Carter has advanced a broad research pipeline of innovative therapeutic candidates addressing significant medical needs in allergy/inflammation and oncology/hematology, while leading the expansion of the company’s core scientific platform to encompass targeted protein degradation. During his time at BMS, Dr. Carter led teams that identified and progressed promising drug candidates through discovery into clinical development. His leadership was also instrumental in advancing BMS’s synthetic chemistry and drug discovery strategies, leading to multiple innovations in both discovery platforms and programs.
“I am delighted to join the Board of Directors at Cellarity as the company sets out to challenge the status quo of drug discovery with its unique platform, ultimately bringing value to patients via novel biology and differentiated drug candidates,” said Dr. Carter. “Cellarity’s platform is unique in that it uses advanced computational methods to decode cell behavior, pinpointing novel biological pathways to uncover drug candidates and ultimately develop highly effective therapies.”
“We are thrilled to add Percy to our experienced Board of Directors to help Cellarity’s management team re-write the rules of drug discovery and drive strong value creation in the years to come,” said Stephen Berenson, Chairman of the Board of Directors of Cellarity and Managing Partner at Flagship Pioneering.
“Percy will bring a diverse and deep set of experiences and expertise to Cellarity as a drug hunter,” said Fabrice Chouraqui, Pharm.D., CEO of Cellarity and a CEO-Partner at Flagship Pioneering. “I look forward to his insights in leveraging the reproducibility of our platform across disease areas and shaping a pipeline of medicines that matter.”
About Cellarity
Founded by Flagship Pioneering in 2019, Cellarity is fundamentally redesigning the way drugs are created. By shifting the starting point of drug discovery from a single target to the cellular dysfunction underlying diseases, the company unravels the complexity of biology to create medicines that are out of reach with the traditional approaches. Cellarity has developed a platform that uses proprietary AI models trained on more than 30 million single cell transcriptomes to discover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in hematology and immunology, as well as an ongoing collaboration with Novo Nordisk in metabolic dysfunction-associated steatohepatitis (MASH). For more information, visit www.cellarity.com.
About Cellarity’s Platform
The Cellarity platform uses proprietary AI models to link biology and chemistry with high-dimensional multi-omics data to uncover novel actionable insights into disease biology and create non-intuitive drug candidates to address a vast array of clinical conditions – including those with limited or unknown targets. The platform has already produced foundational programs in several disease areas, including sickle cell disease (SCD) and MASH (in collaboration with Novo Nordisk).
About Sickle Cell Disease
SCD is a group of inherited red blood cell disorders that require the prevention and treatment of pain episodes, among other complications, and for which current treatments fall short or remain inaccessible to most people living with the condition. Learn more.
About Metabolic Steatohepatitis
Metabolic steatohepatitis, previously known as nonalcoholic steatohepatitis and for which limited treatments exist, is marked by inflammation of the liver caused by excess fat cells in it and eventually leads to progressive liver damage. Learn more.
